XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | Income Taxes Total income before income tax expense summarized by region was as follows (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
United States |  | $ | 557,852 |  |  | $ | 348,828 |  |  | $ | 248,918 |
Foreign |  | (720) |  |  | (499) |  |  | — |
Income before income tax expense |  | $ | 557,132 |  |  | $ | 348,329 |  |  | $ | 248,918 |
Significant components of our net deferred tax assets (liabilities) were as follows (in thousands).
|  | December 31,
|  | 2024 |  | 2023
Deferred tax assets |  |  |  |
Net operating loss carryforwards |  | $ | 20,736 |  |  | $ | 32,753 |
Research and development and orphan drug credits |  | 17,868 |  |  | 38,192 |
Share-based compensation |  | 6,567 |  |  | 5,024 |
ASC 842 lease liability |  | 7,126 |  |  | 7,258 |
Capitalized research expense |  | 30,253 |  |  | 19,543 |
Inventory related reserves |  | 19,867 |  |  | 13,561 |
Other, net |  | 4,206 |  |  | 6,746 |
Total deferred tax assets |  | 106,623 |  |  | 123,077 |
Valuation allowance for deferred tax assets |  | (2,363) |  |  | (2,588) |
Deferred tax assets, net of valuation allowance |  | 104,260 |  |  | 120,489 |
Deferred tax liabilities |  |  |  |
Non-deductible book amortization |  | (89,247) |  |  | (103,492) |
ASC 842 right of use asset |  | (7,882) |  |  | (8,259) |
Other, net |  | (3,276) |  |  | (4,352) |
Total deferred tax liabilities |  | (100,405) |  |  | (116,103) |
Net deferred tax asset |  | $ | 3,855 |  |  | $ | 4,386 |
A valuation allowance of $2.4 million and $2.6 million has been established to offset the net DTAs as of December 31, 2024 and 2023, respectively, as realization of such assets is uncertain. On a periodic basis, we reassess the valuation allowance of our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all our DTAs will be realized. After assessing both positive and negative evidence, we determined that it was more likely than not that our DTAs would be realized except for certain deferred tax assets associated with unrealized cash flow hedge and net operating losses in foreign jurisdictions where we do not expect benefit. Income tax expense (benefit) was comprised of the following components (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
Current - federal |  | $ | 98,139 |  |  | $ | 24,963 |  |  | $ | 6,157 |
Current - state |  | 13,762 |  |  | 5,717 |  |  | 2,525 |
Deferred - federal |  | 1,815 |  |  | 34,037 |  |  | 44,757 |
Deferred - state |  | (675) |  |  | 2,018 |  |  | (6,650) |
Total income tax expense |  | $ | 113,041 |  |  | $ | 66,735 |  |  | $ | 46,789 |
The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due to the following:
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
Federal income tax expense |  | 21.00 | % |  | 21.00 | % |  | 21.00 | %
State income tax expense, net of federal income tax impact |  | 2.25 | % |  | 2.76 | % |  | 0.82 | %
Executive compensation limitation |  | 0.58 | % |  | 0.90 | % |  | 2.61 | %
Foreign-derived intangible income |  | (3.81) | % |  | (3.44) | % |  | (5.06) | %
Research and development credits, net |  | (0.39) | % |  | (2.71) | % |  | — | %
Non-deductible expenses and other |  | 0.66 | % |  | 0.62 | % |  | (0.57) | %
Effective income tax rate |  | 20.29 | % |  | 19.13 | % |  | 18.80 | %
As of December 31, 2024, our unrecognized tax benefit and uncertain tax positions were $24.5 million, of which $23.6 million will impact the effective tax rate when resolved. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of income tax expense. For the years ended December 31, 2024, 2023 and 2022, we recognized an immaterial amount of interest and penalties. The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
|  | Year Ended December 31,
|  | 2024 |  | 2023 |  | 2022
Gross unrecognized tax benefits, beginning of period |  | $ | 21,918 |  |  | $ | 19,482 |  |  | $ | 17,692 |
Increases in tax positions for prior years |  | 2,181 |  |  | 1,645 |  |  | — |
Decreases in tax positions for prior years and lapse in statute of limitations |  | (192) |  |  | — |  |  | (1,148) |
Increases in tax positions related to business acquisition |  | — |  |  | — |  |  | 2,151 |
Increases in tax positions for current year |  | 612 |  |  | 791 |  |  | 787 |
Gross unrecognized tax benefits, end of period |  | $ | 24,519 |  |  | $ | 21,918 |  |  | $ | 19,482 |
As of December 31, 2024, we had California and other state net operating loss carryforwards of approximately $236.9 million and $63.1 million, respectively. The California and other state net operating loss carryforwards begin to expire in 2029. As of December 31, 2024, we had federal and California research and development tax credit carryforwards of approximately $1.1 million, and $25.2 million, respectively. The federal research and development tax credits will begin to expire in 2040 unless previously utilized. The California research and development tax credits will carryforward indefinitely until utilized. Pursuant to Internal Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and development tax credits could be limited by any greater than 50% ownership change during any three-year testing period. As a result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits are subject to annual limitations. We completed an updated Section 382 analysis regarding the limitation of the net operating losses and research and development credits as of the acquisition of Antares. Based upon the analysis, we determined that ownership changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit carryforwards will not have a material impact on the future utilization of such carryforwards. We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to utilize those earnings in the foreign operations for an indefinite period of time. As of December 31, 2024 and 2023, there were no undistributed earnings in foreign subsidiaries. We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2008 and forward are subject to examination by the U.S. federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration